Master Distribution Agreement Sample Clauses

Master Distribution Agreement. See Exhibit Z.
Sample 1Sample 2
AutoNDA by SimpleDocs
Master Distribution Agreement. 2 SECTION 1.9 MERCFUEL BUSINESS..............................................................2 SECTION 1.10 MERCFUEL PRODUCTS............................................................2 SECTION 1.11 MERCFUEL PRODUCTS SCHEDULE...................................................2 SECTION 1.12 MERCFUEL TECHNOLOGY..........................................................2 SECTION 1.13 MERCFUEL TECHNOLOGY SCHEDULE.................................................2 SECTION 1.14 PATENTS......................................................................2 SECTION 1.15 PERSON.......................................................................3 SECTION 1.16 SELL.........................................................................3 SECTION 1.17 SUBSIDIARY...................................................................3 SECTION 1.18 TECHNOLOGY...................................................................3 SECTION 1.19 THIRD PARTY..................................................................3 ARTICLE II - OWNERSHIP.......................................................................3
Sample 1
Master Distribution Agreement. Master Distribution Agreement" means the Master Distribution Agreement between MAG and MercFuel.
Sample 1
Master Distribution Agreement. The Buyer and/or an Affiliate of the Buyer shall have finalized and executed a master distribution agreement with ABC and its Affiliates (the “Master Distribution Agreement”) providing for, among other things, the terms set forth on Exhibit E and which shall be in form and substance reasonably satisfactory to the Buyer.
Sample 1
Master Distribution Agreement. (Class A Shares) The Master Distribution Agreement (the "Agreement"), dated February 28, 1997 by and between AIM International Funds, Inc., a Maryland corporation, with respect to the Class A Shares of each series of shares of common stock as set forth in the Agreement, and A I M Distributors, Inc., a Delaware corporation, is hereby amended as follows: Appendix A of the Agreement is hereby deleted in its entirety and replaced with the following: "APPENDIX A TO MASTER DISTRIBUTION AGREEMENT OF AIM INTERNATIONAL FUNDS, INC. CLASS A SHARES -------------- AIM Asia-Pacific Growth Fund AIM European Capital Growth Fund AIM Global Aggressive Growth Fund AIM Global Growth Fund AIM Global Income Fund AIM International Equity Fund" All other terms and provisions of the Agreement not amended herein shall remain in full force and effect. Dated: __________________________________, 1997 AIM INTERNATIONAL FUNDS, INC. Attest: By: ------------------------------------ ------------------------------------------------------ Assistant Secretary President
Sample 1
Master Distribution Agreement. The Cable Parents and @Home agree to the following terms and conditions relating to the roll-out of the @Home Services in areas served by cable television systems owned by the Cable Parents and their respective Controlled Affiliates:
Sample 1
Master Distribution Agreement. 15 16 The Parties agree to be bound by this Agreement. This Agreement shall be executed in two counterparts, each of which shall be deemed an original for all purposes. A signed copy of the Agreement transmitted by facsimile shall be deemed for all purposes the equivalent of a signed original.
Sample 1
AutoNDA by SimpleDocs
Master Distribution Agreement. (a) GTM hereby appoints ECOLUTIONS, and ECOLUTIONS accepts such appointment, as a non-exclusive Master Distributor for the sale, marketing and distribution of products manufactured using GTM's technology throughout the world, substantially in the form attached hereto as Exhibit A (the “Master Distributor Agreement”). (b) GTM hereby appoints ECOLUTIONS as the exclusive Master Distributor for the sale, marketing and distribution of products manufactured using GTM's technology throughout North America, including the countries of United States of America its commonwealths and territories, Canada, Mexico, and Singapore (hereinafter the “Territory”), subject to the provisions of the attached Exhibit A. (c) Notwithstanding any other provisions of this Agreement, until ECOLUTIONS has established manufacturing described in the License Agreement, GTM will manufacture the products at a manufacturing facility of GTM's choice and ship such products to ECOLUTIONS or its designees. (d) Until the earlier to occur of (i) the expiration or termination of the Master Distribution Agreement, or (ii) three months after ECOLUTIONS's production capability is in place (the “Manufacturing Readiness Date”), GTM will sell products to ECOLUTIONS or its designees at an agreed upon price. Such products will be manufactured by GTM, and sold by ECOLUTIONS in accordance with the provisions of this Agreement. Collaboration Agreement
Sample 1
Master Distribution Agreement. This Amended and Restated Master Distribution Agreement (“Agreement”), dated as of September 1, 2020, is entered into by and between Creative Realities, Inc., a Minnesota corporation (“Master Distributor”), and InReality, LLC, a Wisconsin limited liability company (“Seller”, and together with Master Distributor, the “Parties”, and each, a “Party”).
Sample 1

Related to Master Distribution Agreement

  • Distribution Agreements Subject to compliance with applicable provisions of the 1940 Act, the Board of Trustees may enter into a contract or contracts with one or more Persons to act as underwriters and/or placement agents whereby the Trust may either agree to sell Shares of the Trust, any Series or Class to the other party or parties to the contract or appoint such other party or parties its sales agent or agents for such Shares. In either case, the contract shall be on such terms and conditions as the Board of Trustees may in its discretion determine, not inconsistent with the provisions of this Section 5.12 or the By-laws; and such contract may also provide for the repurchase or sale of Shares of the Trust, any Series or Class by such other party as principal or as agent of the Trust and may provide that such other party may enter into selected dealer agreements with registered securities dealers and brokers and servicing and similar agreements with Persons who are not registered securities dealers to further the purposes of the distribution or repurchase of such Shares.

  • Distribution Agreement This Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and binding obligation of the Company. The transactions contemplated by this Agreement have been duly authorized by the Company.

  • Revenue Sharing Agreement This Note is subject to the Company’s Revenue Sharing Agreement attached hereto as Exhibit B as if all the terms of the Revenue Sharing Agreement were set forth in this Note.

  • Contribution Agreement The Agent shall have received an executed counterpart of the Contribution Agreement.

  • Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.

  • Support Agreement CFSC will not terminate, or make any amendment or modification to, the Support Agreement which, in the determination of the Agent, adversely affects the Banks’ interests pursuant to this Agreement, without giving the Agent and the Banks at least thirty (30) days prior written notice and obtaining the written consent of the Majority Banks.

  • Cooperation Agreement If a Cooperating Institution is appointed, the Fund shall enter into a Cooperation Agreement with the Cooperating Institution setting forth the terms and conditions of its appointment.

  • One Agreement This Agreement and any related security or other agreements required by this Agreement, collectively: (a) represent the sum of the understandings and agreements between the Bank and the Borrower concerning this credit; (b) replace any prior oral or written agreements between the Bank and the Borrower concerning this credit; and (c) are intended by the Bank and the Borrower as the final, complete and exclusive statement of the terms agreed to by them. In the event of any conflict between this Agreement and any other agreements required by this Agreement, this Agreement will prevail.

  • Operating Agreement The Borrower will not amend, modify, waive or terminate any provision of its operating agreement without the prior written consent of the Administrative Agent.

  • Single Agreement All Transactions are entered into in reliance on the fact that this Master Agreement and all Confirmations form a single agreement between the parties (collectively referred to as this “Agreement”), and the parties would not otherwise enter into any Transactions.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!